Drug Trial Radar · NCT06904261
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \< 12 years of age with Fabry disease and with amenable GLA variants.
Conditions
- Fabry Disease
Interventions
Migalastat HCl 20 mgDrug
Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Incidence of TEAEs, SAEs, and AEs leading to discontinuation of study drugTime frame: Day 1 (after dosing) through Month 12 and follow-up (30 days after last dose)
- Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of MigalastatTime frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12
- Pharmacokinetics (PK): Minimum Observed Plasma Concentration (Cmin) of MigalastatTime frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12
- Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve Over The Dosing Interval (AUCtau) of MigalastatTime frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Emory Genetics
Atlanta, Georgia · Recruiting
University of Minnesota Masonic Children's Hospital
Minneapolis, Minnesota · Recruiting
Atrium Health Levine Children's Hospital
Charlotte, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia · Recruiting
Universitair Ziekenhuis (UZ) Leuven
Leuven, Vlaams-Brabant, Belgium · Recruiting
Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine Paediatrie
Münster, North Rhine-Westphalia, Germany · Recruiting
Kitasato University Hospital
Sagamihara, Kanagawa, Japan · Recruiting
Hospital Universitario de la Paz
Madrid, Madrid, Spain · Recruiting
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom · Not yet recruiting
Manchester University NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.